GHK CU is a recurring topic in our peptide coverage. This hub collects every article tagged GHK CU, newest first, each evidence-graded and tied to real, verifiable sources.
Wound healing is one of the few peptide areas with genuine human controlled-trial data — but it is narrow, topical, and concentrated in chronic wounds. A clinical-editorial ranking of GHK-Cu, thymosin β4, LL-37 and BPC-157 by what the evidence actually supports in 2026.
An evidence-graded review of the peptides marketed for wrist sprains, tenosynovitis, TFCC tears and carpal tunnel syndrome. The honest 2026 verdict: no human RCT — indeed essentially no human data of any kind — exists; the case is entirely preclinical (rat tendon and sciatic-nerve models), and conventional care has the far stronger human evidence.
An evidence-first review of the peptides women are sold for skin, sexual desire, weight, hormones and fertility — graded honestly by human data, with the FDA, WADA and pregnancy cautions marketing leaves out.
A clinical, evidence-first ranking of the peptides most promoted for healing surgical incisions and preventing scars — separating genuine human topical-wound data from animal-only signals and marketing.
Tendon is the single best-studied musculoskeletal target for repair peptides — yet no human RCT exists for any peptide in any tendinopathy. We rank BPC-157, TB-500/thymosin β-4 and GHK-Cu strictly by the real evidence.
A clinical look at copper peptides (GHK-Cu) and Matrixyl for striae distensae. No dedicated human trial exists for either — both grade D for stretch marks specifically, despite stronger data on other skin.
A master, evidence-graded overview of the aesthetic peptide field — GHK-Cu, Matrixyl, Argireline, Synthe'6 and the neuromodulator cast — separating small topical human RCTs from in-vitro mechanism and marketing. The honest ceiling is Grade B.
Which cosmetic peptides actually soften wrinkles and photoaging — GHK-Cu, Matrixyl, argireline and more — ranked honestly by the human evidence. All are Grade B: modest, topical, delivery-limited, none Grade A.
A clinical, evidence-first look at the peptides pitched for rotator-cuff tears, labral injury and shoulder tendinopathy — BPC-157, TB-500/thymosin β-4, and GHK-Cu — and why all three are graded C (preclinical only) for the shoulder.
An evidence-graded look at the peptides marketed for rotator-cuff tears and repair recovery — BPC-157, TB-500/Thymosin β4 and GHK-Cu — separating a single unpublished rat abstract and animal mechanism from anything resembling human proof.
A clinical, evidence-graded ranking of the peptides marketed for post-surgical recovery — thymosin alpha-1, thymosin β4/TB-500, GHK-Cu and BPC-157 — separating the one with human surgical RCT data from the rest, which are topical, negative, or preclinical only.
An evidence-graded review of the peptides marketed for osteoarthritis and joint degeneration. The honest 2026 verdict: the strongest human data belongs not to any joint-repair peptide but to GLP-1 metabolic drugs that relieve knee-OA pain by removing mechanical load.
A clinical, evidence-first ranking of the peptides marketed for the menopause transition — separating the one FDA-approved molecule from the population-borrowed, preclinical, and mechanistically backwards claims.
An evidence-graded review of the peptides marketed for meniscus tears, ligament sprains, tendinopathy and cartilage wear. The honest 2026 verdict: no peptide has a placebo-controlled human knee trial — the strongest case is preclinical (rat surgery models) plus one uncontrolled human case series.
A clinical, evidence-graded review of the peptides marketed for joint health and joint pain — BPC-157, TB-500/thymosin β-4, GHK-Cu and ARA-290 — ranked honestly by the strength of their human vs preclinical data.
An evidence-graded review of the peptides marketed to 'injury-proof' tendons and ligaments. The honest 2026 verdict: prevention is the single most speculative claim in the peptide literature — no human prevention RCT, and no controlled animal prevention study, exists for any candidate.
An evidence-graded review of the peptides marketed for hip labral tears, femoroacetabular impingement, gluteal tendinopathy (GTPS) and hip bursitis. The honest 2026 verdict: no peptide has a human hip trial — the evidence tops out at animal models, while exercise and PRP hold the real human RCT data.
An evidence-graded ranking of the peptides marketed for hair thinning, density, and shedding — separating the modest human topical data from the mechanistic and mouse-only hype.
An evidence-graded ranking of the peptides marketed for androgenetic alopecia — zinc-thymulin, biotinoyl tripeptide-1/Procapil, GHK-Cu copper peptide, and PTD-DBM — separating the small human data from mouse work, blends, and marketing.
A clinical, evidence-graded ranking of the peptides studied for bone — from the FDA-approved PTH-class anabolics with Grade A fracture-prevention RCTs to the entirely preclinical regenerative peptides.
GHK CU is a topic our editors cover across the site. This hub aggregates the related, evidence-graded guidance.
This hub updates automatically whenever a new article is tagged GHK CU, so the latest coverage appears first.
Yes. Every article here grades its efficacy claims A-D and cites real, verifiable studies, regulatory documents or trial registries.
The majority of compounds documented here are not approved by the FDA for human use. Approved drugs (e.g. semaglutide, tirzepatide) are noted explicitly and require a licensed prescriber.
Many peptides — including BPC-157 and GHK-Cu in injectable form — are sold strictly "for research use only — not for human consumption." Purity, identity, and dosing of such products are not regulated or guaranteed.
Several compounds are banned in competitive sport under the WADA Prohibited List. Athletes risk sanction regardless of intent or formulation.
Always consult a qualified, licensed healthcare professional before considering any compound. Individual risk depends on your full medical context.
This content is for informational and educational purposes only · No physician–patient relationship is created · Evidence grades reflect published data as of the stated revision and may change.